In summary, HIF-1α, BRAF mutations, and TSHR signaling synergistically contribute to metabolic plasticity in thyroid cancer, representing key mechanisms underlying metabolic reprogramming and drug resistance. The gene discussed is HIF1A; the disease is thyroid cancer.